BACE2-IN-1

• CAT Number: I043464
• CAS Number: 1676107-08-6
• Molecular Formula: C36H38F3N3O3
• Molecular Weight: 617.70
• Purity: ≥95%
• Synonyms: 1-N-[(2S,3R)-3-hydroxy-1-phenyl-4-[[3-(trifluoromethyl)phenyl]methylamino]butan-2-yl]-3-N,5-dimethyl-3-N-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide
• InChI: InChI=1S/C36H38F3N3O3/c1-24-17-29(21-30(18-24)35(45)42(3)25(2)28-14-8-5-9-15-28)34(44)41-32(20-26-11-6-4-7-12-26)33(43)23-40-22-27-13-10-16-31(19-27)36(37,38)39/h4-19,21,25,32-33,40,43H,20,22-23H2,1-3H3,(H,41,44)/t25-,32+,33-/m1/s1
• InChIKey: KQGVKXJLEHXBDS-CBHGIOBQSA-N
• SMILES: CC1=CC(=CC(=C1)C(=O)N(C)[C@H](C)C2=CC=CC=C2)C(=O)N[C@@H](CC3=CC=CC=C3)[C@@H](CNCC4=CC(=CC=C4)C(F)(F)F)O

BACE2-IN-1（Cat No.:I043464）is a selective inhibitor of the Beta-Site APP Cleaving Enzyme 2 (BACE2), an enzyme involved in the processing of amyloid precursor protein (APP) and implicated in neurodegenerative diseases like Alzheimer’s disease. By inhibiting BACE2, BACE2-IN-1 aims to reduce the production of toxic amyloid-beta peptides, which aggregate to form plaques in the brain, contributing to disease progression. This compound serves as a potential therapeutic agent for neurodegenerative diseases, offering a targeted approach to modulate APP processing and mitigate amyloid-related toxicity while minimizing side effects associated with BACE1 inhibition.